Skip to content

Sound and Vision: A Collaboration Between Service-users, Artists and the Public to Explore the Lived Experience of Hallucinations

Sound and Vision: A Collaboration Between Service-users, Artists and the Public to Explore the Lived Experience of Hallucinations

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04399096
Enrollment
500
Registered
2020-05-22
Start date
2020-12-01
Completion date
2021-12-31
Last updated
2021-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hallucinations, Parkinson Disease, Schizophrenia

Keywords

hallucination

Brief summary

Sound and Vision: A collaboration between service-users, artists and the public to explore the lived experience of hallucinations

Detailed description

Sound and Vision will pair local artists with patients who have had hallucinations to create art pieces that represent their hallucinatory experiences. Patients with diagnoses of schizophrenia and Parkinson's disease will be invited to take part in participating National Health Service (NHS) clinics, to capture and compare a wide range of hallucinatory experiences. Patients will meet with artists on several occasions who will then develop the piece, which may be a painting, drawing, or other media that the artist and service-user jointly select. Completed artworks will be the centrepiece for an exhibition at United Kingdom (UK) science festivals and a digital (on-line) presentation. The exhibition will be accompanied by researchers explaining the brain science of hallucinations, recordings of patients and artists describing their experience with hallucinations and the process of developing the artworks, booklets cataloguing the exhibition, and art materials available for artistic expression of their own experiences. A digital compendium of the artworks and supporting material will be publicly available alongside the opportunity to complete an online survey exploring the themes of the artworks and collecting information on personal experiences. The objectives are to engage the public in an appreciation of the experience of hallucinations and their prevalence across many common mental health and neurodegenerative disorders, as well as an experience many people will share without ever being diagnosed. The exhibition will also encourage the public to share their own experiences through the online questionnaires creating a platform to begin to improve the understanding of the diversity of hallucination-like experiences in the general population.

Interventions

None listed

Sponsors

Cambridge University Hospitals NHS Foundation Trust
CollaboratorOTHER
Cambridgeshire and Peterborough NHS Foundation Trust
CollaboratorOTHER
University of Cambridge
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

No particular inclusion or

Design outcomes

Primary

MeasureTime frameDescription
University of Miami Parkinson's disease Hallucinations Questionnaire (UM-PDHQ)Through study completion, an average of 1 yearThe University of Miami Parkinson's disease Hallucinations Questionnaire (UM-PDHQ) is composed of 6 quantitative and 14 qualitative items to define the key characteristics of hallucinations in Parkinson's Disease. The first 6 questions score the severity of hallucinations with a minimum score is zero and a maximum of 14, with greater score indicating greater severity. The remaining 14 questions have qualitative answers.
The Multi-Modality Unusual Sensory Experiences Questionnaire (MUSEQ)Through study completion, an average of 1 yearThe Multi-Modality Unusual Sensory Experiences Questionnaire (MUSEQ) is a 43-item self-report measure with each item rated on a five-point Likert scale, and assesses unusual sensory experiences in six modalities: auditory, visual, olfactory, gustatory, bodily sensations, and sensed presence. The minimum score is zero, the maximum score is 173 with a greater score indicating a higher frequency of unusual sensory experiences.

Countries

United Kingdom

Contacts

Primary ContactJohn Suckling
js369@cam.ac.uk01223 336063
Backup ContactColleen Rollins
cper2@cam.ac.uk01223 336585

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026